Tags

Type your tag names separated by a space and hit enter

Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study.
Aliment Pharmacol Ther 2010; 31(6):615-24AP

Abstract

BACKGROUND

Alverine citrate and simeticone combination has been used for almost 20 years in irritable bowel syndrome (IBS), but supportive scientific evidence of efficacy was limited.

AIM

To evaluate the efficacy of alverine citrate and simeticone combination in patients with IBS-related abdominal pain/discomfort.

METHODS

A total of 412 IBS patients meeting ROME III criteria were included in this double-blind randomized placebo-controlled study if their abdominal pain/discomfort intensity was at least 60 mm on a 0-100 mm visual analogue scale (VAS) during a 2-week run-in treatment-free period. Patients were randomly assigned through the use of Interactive Voice Response System to receive either alverine citrate 60 mg with simeticone 300 mg three times daily or matching placebo for 4 weeks.

RESULTS

The full analysis set included 409 patients (71.4% female: mean age: 46.2 +/- 13.9 years). At week 4, alverine citrate and simeticone group had lower VAS scores of abdominal pain/discomfort (median: 40 mm vs. 50 mm, P = 0.047) and higher responder rate (46.8% vs. 34.3%, OR = 1.3; P = 0.01) as compared with placebo group. Patient receiving alverine citrate and simeticone reported greater global symptom improvement compared with those receiving placebo (P = 0.0001). Reported adverse events were similar in both groups.

CONCLUSION

Alverine citrate/simeticone combination was significantly more effective than placebo in relieving abdominal pain/discomfort in patients with IBS.

Authors+Show Affiliations

First Department of Medicine, University of Szeged, Szeged, Hungary. witt@in1st.szote.u-szeged.huNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20003095

Citation

Wittmann, T, et al. "Clinical Trial: the Efficacy of Alverine Citrate/simeticone Combination On Abdominal Pain/discomfort in Irritable Bowel Syndrome--a Randomized, Double-blind, Placebo-controlled Study." Alimentary Pharmacology & Therapeutics, vol. 31, no. 6, 2010, pp. 615-24.
Wittmann T, Paradowski L, Ducrotté P, et al. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2010;31(6):615-24.
Wittmann, T., Paradowski, L., Ducrotté, P., Bueno, L., & Andro Delestrain, M. C. (2010). Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study. Alimentary Pharmacology & Therapeutics, 31(6), pp. 615-24. doi:10.1111/j.1365-2036.2009.04216.x.
Wittmann T, et al. Clinical Trial: the Efficacy of Alverine Citrate/simeticone Combination On Abdominal Pain/discomfort in Irritable Bowel Syndrome--a Randomized, Double-blind, Placebo-controlled Study. Aliment Pharmacol Ther. 2010;31(6):615-24. PubMed PMID: 20003095.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study. AU - Wittmann,T, AU - Paradowski,L, AU - Ducrotté,P, AU - Bueno,L, AU - Andro Delestrain,M-C, Y1 - 2009/12/10/ PY - 2009/12/17/entrez PY - 2009/12/17/pubmed PY - 2010/7/31/medline SP - 615 EP - 24 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 31 IS - 6 N2 - BACKGROUND: Alverine citrate and simeticone combination has been used for almost 20 years in irritable bowel syndrome (IBS), but supportive scientific evidence of efficacy was limited. AIM: To evaluate the efficacy of alverine citrate and simeticone combination in patients with IBS-related abdominal pain/discomfort. METHODS: A total of 412 IBS patients meeting ROME III criteria were included in this double-blind randomized placebo-controlled study if their abdominal pain/discomfort intensity was at least 60 mm on a 0-100 mm visual analogue scale (VAS) during a 2-week run-in treatment-free period. Patients were randomly assigned through the use of Interactive Voice Response System to receive either alverine citrate 60 mg with simeticone 300 mg three times daily or matching placebo for 4 weeks. RESULTS: The full analysis set included 409 patients (71.4% female: mean age: 46.2 +/- 13.9 years). At week 4, alverine citrate and simeticone group had lower VAS scores of abdominal pain/discomfort (median: 40 mm vs. 50 mm, P = 0.047) and higher responder rate (46.8% vs. 34.3%, OR = 1.3; P = 0.01) as compared with placebo group. Patient receiving alverine citrate and simeticone reported greater global symptom improvement compared with those receiving placebo (P = 0.0001). Reported adverse events were similar in both groups. CONCLUSION: Alverine citrate/simeticone combination was significantly more effective than placebo in relieving abdominal pain/discomfort in patients with IBS. SN - 1365-2036 UR - https://www.unboundmedicine.com/medline/citation/20003095/Clinical_trial:_the_efficacy_of_alverine_citrate/simeticone_combination_on_abdominal_pain/discomfort_in_irritable_bowel_syndrome__a_randomized_double_blind_placebo_controlled_study_ L2 - https://doi.org/10.1111/j.1365-2036.2009.04216.x DB - PRIME DP - Unbound Medicine ER -